Биостатистика, фармакокинетика и клинические исследования.

Домашняя страница
- О сайте
Материалы
- Быстрые команды R Project
- Ссылки
Инструменты
- Рандомизационный список
Блог
Контакты
Профиль
- Войти
- Зарегистрироваться

Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
Главные ошибки при формировании базы данных в MS Excel
Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
Julia:ReplicateBE – release 0.2.0

Галерея

Consumer Updates
Source: FDA - What's New: Drugs RSS Feed Published on 2023-12-09 By FDA
CASGEVY
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-12-08 By FDA
LYFGENIA
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-12-08 By FDA
Administrative Guidances
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-12-08 By FDA
FDA Roundup: December 8, 2023
Source: FDA - What's New: Drugs RSS Feed Published on 2023-12-08 By FDA
COVID-19 Vaccines
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-12-08 By FDA
Product Quality Research Institute (PQRI) Workshop: MIDD Approaches in Pediatric Formulation Development - 02/28/2024
Source: FDA - What's New: Drugs RSS Feed Published on 2023-12-08 By FDA
Licensed Biological Products with Supporting Documents
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-12-08 By FDA
Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-12-08
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-12-08 By FDA
Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 20, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-12-08
Human medicines European public assessment report (EPAR): Atriance, nelarabine, Date of authorisation: 22/08/2007, Revision: 27, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-12-08
Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Date of authorisation: 09/03/2004, Revision: 24, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-12-08
Human medicines European public assessment report (EPAR): Spravato, esketamine, Date of authorisation: 18/12/2019, Revision: 9, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-12-08
Human medicines European public assessment report (EPAR): Zilbrysq, Zilucoplan, Date of authorisation: 01/12/2023, Status: Authorised
Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-12-08

Предыдущие записи

Тема: Scaffold от Danny Cooper.